Search Within

Margaret Kathleen Callahan

Formats
  1. Journal Article (105)
  2. Meeting Abstract (84)
  3. Editorial (4)
  4. Book Section (2)
  5. Research Letter (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Department of Medicine (199)
  2. Melanoma and Immunotherapeutics Service (199)
  3. Solid Tumor Oncology Division (199)
  4. GSK Faculty (123)
  5. Melanoma Disease Management Team (108)
  6. Hematologic Malignancies, Division of (77)

More Groups

People
  1. Jedd Wolchok (113)
  2. Michael Postow (96)
  3. Paul Chapman (50)
  4. Alexander Shoushtari (46)
  5. Katherine Panageas (38)
  6. Parisa Momtaz (30)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (11)
  6. 2020 (19)

More Years

Publications
  1. Journal of Clinical Oncology (61)
  2. Journal for ImmunoTherapy of Cancer (17)
  3. Science Translational Medicine (10)
  4. Annals of Oncology (7)
  5. Clinical Cancer Research (7)
  6. New England Journal of Medicine (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Biomed Central Ltd (17)
  3. American Association for Cancer Research (15)
  4. Elsevier Inc. (15)
  5. Oxford University Press (15)
  6. Nature Publishing Group (11)

More Publishers

Results (199)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors
    Meeting Abstract

    Ott, P. A.; Callahan, M. K.; Odunsi, K.; Park, A. J.; Pan, L. S.; Venhaus, R. R.; Karakunnel, J. J.; Hodi, F. S.; Wolchok, J. D.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab
    Meeting Abstract

    Munhoz, R. R.; Merghoub, T.; Emerson, R. O.; Callahan, M. K.; Wolchok, J. D.; Postow, M. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab (ipi) over 30 minutes (min)
    Meeting Abstract

    Momtaz, P.; Park, V.; Panageas, K.; Guillen, J. D.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    Journal Article

    Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Immune checkpoint blockade in cancer therapy
    Journal Article

    Postow, M. A.; Callahan, M. K.; Wolchok, J. D.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
    Journal Article

    Lesokhin, A. M.; Callahan, M. K.; Postow, M. A.; Wolchok, J. D.
    Science Translational Medicine (2015)

    Fulltext@MSK | Save
  • Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo
    Journal Article

    Das, R.; Verma, R.; Sznol, M.; Boddupalli, C. S.; Gettinger, S. N.; Kluger, H.; Callahan, M.; Wolchok, J. D.; Halaban, R.; Dhodapkar, M. V.; more...
    Journal of Immunology (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Meeting Abstract

    Puzanov, I.; Callahan, M. K.; Linette, G. P.; Patel, S. P.; Luke, J. J.; Sosman, J. A.; Wolchok, J. D.; Hamid, O.; Minor, D. R.; Orford, K. W.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Meeting Abstract

    Callahan, M. K.; Ott, P. A.; Odunsi, K.; Bertolini, S. V.; Pan, L. S.; Venhaus, R. R.; Karakunnel, J. J.; Hodi, F. S.; Wolchok, J. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save